An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
The myostatin/activin type II receptor (ActRII) pathway has been identified to be critical in regulating skeletal muscle size. Several other ligands, including GDF11 and the activins, signal through this pathway, suggesting that the ActRII receptors are major regulatory nodes in the regulation of muscle mass. We have developed a novel, human anti-ActRII antibody (bimagrumab, or BYM338) to prevent binding of ligands to the receptors and thus inhibit downstream signaling. BYM338 enhances differentiation of primary human skeletal myoblasts and counteracts the inhibition of differentiation induced by myostatin or activin A. BYM338 prevents myostatin- or activin A-induced atrophy through inhibition of Smad2/3 phosphorylation, thus sparing the myosin heavy chain from degradation. BYM338 dramatically increases skeletal muscle mass in mice, beyond sole inhibition of myostatin, detected by comparing the antibody with a myostatin inhibitor. A mouse version of the antibody induces enhanced muscle hypertrophy in myostatin mutant mice, further confirming a beneficial effect on muscle growth beyond myostatin inhibition alone through blockade of ActRII ligands. BYM338 protects muscles from glucocorticoid-induced atrophy and weakness via prevention of muscle and tetanic force losses. These data highlight the compelling therapeutic potential of BYM338 for the treatment of skeletal muscle atrophy and weakness in multiple settings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“blocking these receptors can result in profound muscle growth in animals and humans18–22”
From GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates (2025) · cites this paper as [19]
In the citing paper
“Interestingly, STC2 is among the genes that are downregulated in skeletal muscle from mice following bimagrumab (activin type II receptor antagonist) treatment [149].”
From Main Pathogenic Mechanisms and Recent Advances in COPD Peripheral Skeletal Muscle Wasting (2023) · cites this paper as [149]
In the citing paper
“Myostatin is secreted by the myocytes and inhibits their differentiation and proliferation.”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [95]
In the citing paper
“Myostatin and Activin receptor type 2 (ActRII) inhibitors have been developed and shown to increase muscle mass and strength and as well as improve insulin sensitivity in vitro (94, 95).”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [95]
In the citing paper
“Its level increased in individuals with sarcopenia and/or obesity.”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [95]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Bodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J. C., Glass, D. J., et al. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1014 · Cited by 2,752 · cited 1×
“This restoration of AKT phosphorylation is important, since AKT has been shown in prior studies to be required for weight-bearing-induced skeletal muscle hypertrophy; we have also previously shown that AKT activates mTOR-mediated phosphorylation of p70S6 kinase in skeletal muscle (49) and inhibits GSK3, resulting in m…”
BackgroundSelf-citationDouble muscling in cattle due to mutations in the myostatin gene
McPherron, A. C., & Lee, S.-J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12457 · Cited by 2,039 · cited 1×
“In addition to myostatin (5, 6), other negative regulators of muscle mass have been reported to signal through ActRIIB, including activin A (10–13), while some uncertainty with regard to the contribution of the closely related GDF11 at regulating muscle mass and function remains (13–15).”
BackgroundRegulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616 · cited 3×
“Prior studies had suggested this as well (10, 18), but this is the first demonstration that an antibody directed at the ActRII receptor can induce significantly greater hypertrophy than myostatin inhibition alone; the point had been made with the ActRIIB trap, but that molecule can actually also bind other ligands tha…”
BackgroundRommel, C., Bodine, S. C., Clarke, B. A., Rossman, R., Nunez, L., Stitt, T. N., Yancopoulos, G. D., & Glass, D. J. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1009 · Cited by 1,583 · cited 1×
“This restoration of AKT phosphorylation is important, since AKT has been shown in prior studies to be required for weight-bearing-induced skeletal muscle hypertrophy; we have also previously shown that AKT activates mTOR-mediated phosphorylation of p70S6 kinase in skeletal muscle (49) and inhibits GSK3, resulting in m…”
BackgroundSelf-citationMyostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Clop, A., Marcq, F., Takeda, H., Pirottin, D., Tordoir, X., Bibé, B., Bouix, J., Caiment, F., Elsen, J.-M., Eychenne, F., et al. (2006) · Nature Genetics · doi:10.1038/ng1810 · Cited by 1,260
Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival
Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T., Simonet, W. S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.011 · Cited by 940 · cited 3×
“Intervention at the ActRIIB pathway level under cancer cachexia conditions in mice showed a clear benefit not only for muscle preservation but also for overall survival, without affecting tumor growth (24).”
BackgroundInduction of Cachexia in Mice by Systemically Administered Myostatin
Zimmers, T. A., Davies, M. V., Koniaris, L. G., Haynes, P., Esquela, A. F., Tomkinson, K. N., McPherron, A. C., Wolfman, N. M., & Lee, S.-J. (2002) · Science · doi:10.1126/science.1069525 · Cited by 907
Mosher, D. S., Quignon, P., Bustamante, C. D., Sutter, N. B., Mellersh, C. S., Parker, H. G., & Ostrander, E. A. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030079 · Cited by 826
Research works printed but not linked: 1
- Glass D, 2010, Curr. Top. Microbiol. Immunol., 346, 267
Cited by
Items 201–300 of 305
Wei, M., He, S., Zhang, X., Meng, D., Yang, G., & Wang, Z. (2025) · BMC Geriatrics · doi:10.1186/s12877-025-06529-w · Cited by 10
“Even novel, more selective targeted therapies developed in the last decade have failed to demonstrate consistent efficacy in larger clinical trials [18, 19].”
Where are we now in biologic drugs for myositis?
Neves, A., Viveiros, L., Venturelli, V., & Isenberg, D. A. (2024) · Rheumatology · doi:10.1093/rheumatology/keae096 · Cited by 11
“Bimagrumab is a fully human, recombinant monoclonal antibody targeting the activin type 2 receptor, preventing its binding to myostatin, and inhibiting negative regulation of muscle hypertrophy (98).”
Snedden, A. M., Lilleker, J. B., & Chinoy, H. (2021) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-020-00169-4 · Cited by 11
Kostyunina, D. S., Ivanova, A. D., & Smirnova, О. V. (2018) · Human Physiology · doi:10.1134/s0362119718010127 · Cited by 13
“Moreover, antibodies interacting with the ACVR2B receptor (bymagrumab or BYM338) and thereby blocking its binding to myostatin were been synthesized [76].”
BackgroundEmerging drugs for the treatment of sarcopenia in cirrhosis of the liver
Cola, S. D., Khan, S., Lapenna, L., & Merli, M. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2332428 · Cited by 10
“Bimagrumab is a fully human monoclonal antibody that blocks both receptor subtypes, ActRIIA and ActRIIB, thereby promoting the differentiation of myoblasts [79].”
BackgroundBrady, S., Poulton, J., & Muller, S. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103644 · Cited by 10
Egerman, M. A., Zhang, Y., Donné, R., Xu, J., Gadi, A., McEwen, C., Salmon, H. A., Xiong, K., Bai, Y., Germino, M., et al. (2025) · Skeletal Muscle · doi:10.1186/s13395-025-00373-7 · Cited by 9
“It was previously shown that a selective anti-ActRIIA/B monoclonal antibody was sufficient to block downstream signaling and effects of ActA and GDF8 in skeletal muscle [16].”
InfluentialSelf-citationGDF11 protein as a geroprotector
Khavinson, V. K., Bi, K., Tarnovskaya, S. I., & Linkova, N. S. (2016) · Biology Bulletin Reviews · doi:10.1134/s207908641602002x · Cited by 8
“These receptors mediate the GDF11 and activin effects on the skeletal muscles (LachhTrifilieff et al., 2014).”
Drugs for the Treatment of Muscle Atrophy
Chen, L., Zhang, H., Chi, M., Yang, Q., & Guo, C. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.93503 · Cited by 11
The double mutations of acvr2aa and acvr2ba leads to muscle hypertrophy in zebrafish
Che, J., Hu, C., Wang, Q., Fan, C., Si, Y., Gong, X., & Bao, B. (2022) · Aquaculture and Fisheries · doi:10.1016/j.aaf.2022.03.007 · Cited by 9
Expression Profiling of Activin type IIB Receptor During Ontogeny in Broiler and Indigenous Chicken
Vishnu, P. G., Bhattacharya, T. K., Kumar, T. V., CHATTERJEE, R. N., Kumar, G. V. P. P. S. R., Paswan, C., Reddy, D. K., & Prasad, A. R. (2016) · Animal Biotechnology · doi:10.1080/10495398.2016.1194287 · Cited by 11
Thevis, M., Walpurgis, K., Thomas, A., & Geyer, H. (2019) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2019.05.004 · Cited by 9
Endpoint choice for inclusion body myositis: a step too far?
Schmidt, J. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30279-0 · Cited by 11
Identification of ligand-selective peptidic ActRIIB-antagonists using phage display technology
Sakamoto, K., Kanematsu‐Yamaki, Y., Kamada, Y., Oka, M., Ohnishi, T., Miwa, M., Asami, T., & Inooka, H. (2017) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2017.06.001 · Cited by 8
“In addition to blockers that mask MSTN, the ActRIIB antagonist antibody BYM-338 has been studied [8].”
BackgroundCombined angiogenic and hypertrophic gene therapy enhances skeletal muscle growth
Männistö, A., Tonttila, K., Ortega‐Alonso, A., Nurmi, H. J., Uusitalo‐Kylmälä, L., Hemanthakumar, K. A., Saikkala, E., Myllykangas, S., Vertainen, S., Nissinen, T. A., et al. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00966.2024 · Cited by 8
Fat, muscle, and anti-obesity medications in cardiovascular disease prevention
Khan, M. S., Dawood, M. H., Handelsman, Y., Anker, S. D., Coats, A. J. S., Green, J. B., & Butler, J. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag201 · Cited by 9
Fibronectin-based scaffold domain proteins that bind myostatin: a patent evaluation of WO2014043344
Walker, R. G., & Thompson, T. B. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1007954 · Cited by 7
Molecular Pathways Governing the Termination of Liver Regeneration
de Haan, L. R., van Golen, R. F., & Heger, M. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.000955 · Cited by 11
Kim, J. H., Kim, J., Jang, J., Jang, J., Jin, D., Kim, Y., & Jin, H. (2021) · Molecules · doi:10.3390/molecules26092676 · Cited by 10
Diagnosis and management of sarcopenia
Choi, J., & Kim, K. (2024) · Journal of Korean Medical Association · doi:10.5124/jkma.2024.67.7.461 · Cited by 10
Welling, M. S., van Rossum, E. F. C., & van den Akker, E. L. T. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf004 · Cited by 9
Samali, S. A., Hosseini, S. F., Mohammadi, Y., Sadri, F., & Rezaei, Z. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11390-6 · Cited by 9
“Preclinical and translational data further show potent hypertrophic effects, reversal of atrophy, and improvements in metabolic parameters through Smad2/3 inhibition and Akt-indepen-dent mechanisms [61, 62].”
Pharmacological targeting of age-related changes in skeletal muscle tissue
Leuchtmann, A. B., & Handschin, C. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.02.030 · Cited by 9
“Since the myostatin receptor complex 225 (activin type IIB receptor and activin receptor‐like kinase 4 or 5) is activated by multiple ligands, 226 blockage of receptor function might be a more promising approach [80].”
Generation of reporter cell lines for factors inducing muscle wasting in cancer cachexia
Cao, Z., Jose, I., Glab, J., Puthalakath, H., Osellame, L. D., & Hoogenraad, N. J. (2020) · Analytical Biochemistry · doi:10.1016/j.ab.2020.113877 · Cited by 6
Protective Effect of Delta-Like 1 Homolog Against Muscular Atrophy in a Mouse Model
Lee, J. Y., Lee, M., Lee, D.-H., Lee, Y., Lee, B., Kang, E. S., & Soo, B. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1446 · Cited by 7
“Phosphorylated Smad2/3 leads to down-regulation of myogenic genes such as MyoD and myogenin [18].”
BackgroundSalemi, S., Schori, L. J., Gerwinn, T., Horst, M., & Eberli, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054462 · Cited by 6
Bigford, G. E., Donovan, A., Webster, M. T., Dietrich, W. D., & Nash, M. S. (2021) · Journal of Neurotrauma · doi:10.1089/neu.2021.0061 · Cited by 7
“56 As a pharmacotherapeutic strategy, human trials examining myostatin inhibition in diseases and disorders of muscle wasting, including chronic obstructive pulmonary disease (COPD) cachexia, and aging-related frailty have successfully demonstrated increases in lean mass. 57 In addition, recent…”
GDF8 Contributes to Liver Fibrogenesis and Concomitant Skeletal Muscle Wasting
Culver, A. E., Hamang, M., Wang, Y., Jiang, H., Yanum, J. A., White, E., Gawrieh, S., Vuppalanchi, R., Chalasani, N., Dai, G., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11071909 · Cited by 6
Mo, C.-L., Wang, Z.-Y., Bonewald, L., & Brotto, M. (2017) · Molecular and integrative toxicology · doi:10.1007/978-3-319-56192-9_9
Mori‐Yoshimura, M., Yamashita, S., Suzuki, N., Katsuno, M., Murata, K., Nodera, H., Teshima, R., Inamura, T., Nishino, I., & Aoki, M. (2019) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.cn-001325 · Cited by 5
Pinètre, J., Delcourt, V., Bécher, F., Garcia, P., Barnabé, A., Loup, B., Popot, M., Fenaille, F., & Bailly‐Chouriberry, L. (2023) · Drug Testing and Analysis · doi:10.1002/dta.3525 · Cited by 5
Jin, Y., Schultz, H., Ongaro, L., Schang, G., Zhou, X., Alonso, C. A. I., Zamojski, M., Nudelman, G., Mendelev, N., Onuma, S., et al. (2026) · Endocrinology · doi:10.1210/endocr/bqag020 · Cited by 3
Exercise-induced myokines in metabolic regulation: mechanisms, mimetics, and translational potential
Aslam, M. A., Lee, J., Bowen, T. S., & Huh, J. Y. (2026) · Archives of Pharmacal Research · doi:10.1007/s12272-026-01624-x · Cited by 10
“However, this pathway is not fully myostatin-specific, because ActRII-directed interventions also affect signaling by other TGF-β family ligands, including activins and GDF11 (Lach-Trifilieff et al. 2014; Morvan et al. 2017).”
Applications of Myostatin in Poultry and Aquaculture - A Review
Shoyombo, A. J., Abdulmojeed, Y., Alabi, O. O., Popoola, M. A., Okon, E. M., & Arije, D. O. (2022) · The Open Agriculture Journal · doi:10.2174/18743315-v16-e2208010 · Cited by 7
Boido, M., Butenko, O., Filippo, C., Schellino, R., Vrijbloed, J. W., Fariello, R. G., & Vercelli, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228653 · Cited by 4
“At first sight, the results were similar to what has previously been described for a myostatin inhibitor, but MWs and BWs were only very moderately increased [18, 19, 23], possibly because of poor tissue penetration of (m)ActR-Fc-nLG3.”
ResultOsteoporosis Associated with Chronic Kidney Disease
Ott, S. M., & Elder, G. J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00058-3 · Cited by 5
Activité physique et nutrition après diagnostic d’un cancer
Bachmann, P., Foucaut, A.-M., Baudinet, C., Meyrand, R., Kempf-Lépine, A.-S., Berthouze, S., Fervers, B., & Touillaud, M. S. (2014) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2014.10.007 · Cited by 9
Oxytocin treatment reduces cancer cachexia in a pre-clinical model
Sviercovich, A., Watanabe, E., Fernandez, E. S., Renzini, A., Liu, C., Xie, G., Cao, J., Li, Z., Agbulut, O., Seelaender, M. C. L., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118825 · Cited by 3
Therapeutic potential of muscle growth promoters in a stress urinary incontinence model
Yang, J., Balog, B. M., Deng, K., Hanzlicek, B., Rietsch, A. M., Kuang, M., Hatakeyama, S., Lach‐Trifilieff, E., Zhu, H., & Damaser, M. S. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00122.2020 · Cited by 5
Self-citationINFLAMMAGING IN MUSCLE: THE MISSING LINK BETWEEN SARCOPENIA AND IDIOPATHIC INFLAMMATORY MYOPATHIES
Jagtap, K., Hoff, L. S., Conticini, E., Naveen, R., & Gupta, L. (2022) · Anti-Aging Eastern Europe · doi:10.56543/aaeeu.2022.1.1.10 · Cited by 4
“Bimagrumab/ BYM338 (human anti-ActRII antibody) blocks the binding of myostatin to its activin 2 receptor [48].”
Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults
Tarazi, M. S., Touhamy, S., Tchang, B. G., & Shukla, A. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1942841 · Cited by 4
“Activation of these receptors promote muscle atrophy; bimagrumab blocks their signaling, which promotes an increase in skeletal muscle mass [105].”
BackgroundIdentification of a bone morphogenetic protein type 2 receptor neutralizing antibody
Gorrell, R. E., Totten, M. H., Schoerning, L., Newby, J. B., Geyman, L. J., Oms, W. G. L., Hum, J. M., & Lowery, J. W. (2019) · BMC Research Notes · doi:10.1186/s13104-019-4367-0 · Cited by 3
Reframing fibrosis as a barrier to regeneration and gene delivery in muscular diseases
Kılıç, H. B., & Kocaefe, Ç. (2026) · FEBS Journal · doi:10.1111/febs.70427 · Cited by 3
“In preclinical studies, administration of a myostatin-blocking antibody led to a significant increase in muscle mass of up to 25% in murine models and insulin sensitization in old mice [70,71].”
Cadena, S. M., Bogdanovich, S., Khurana, T. S., Pullen, A. E., Pearsall, R. S., Curran, E., Faucette, R., Lane, J., Seehra, J. S., Lachey, J. L., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0342666 · Cited by 2
“…of activin A [39,58–60], including the administration of a murine analog of ACE-031 (RAP-031, the extracellular region of ActRIIB fused to the Fc region of a murine IgG2) [32,33,59,61,62] and a monoclonal antibody against ActRIIA and ActRIIB [63,64] in models of muscle wasting and degeneration.”
Carollo, L., Lawson, E. A., Stanley, T. L., Wang, J., Bhattacharya, R., Bishop, D. J., Carmichael, O. T., Esser, K. A., Febbraio, M. A., Fielding, R. A., et al. (2026) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2026.101262 · Cited by 3
“Mechanisti-cally, ActRII inhibition acts on the PI3K/Akt/mTOR signaling axis, a regulator of anabolic processing, to support protein synthesis and muscle growth [133,134].”
Rooks, D., Yates, D. P., Neelakantham, S., Praestgaard, J., Cury, R. C., Lamb, H. J., Roubenoff, R., Pétricoul, O., Lach‐Trifilieff, E., & Svensson, E. C. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag091 · Cited by 4
Self-citationVaughan, D., Kretz, O., Alqallaf, A., Mitchell, R., der Heide, J. L. V., Vaiyapuri, S., Matsakas, A., Pasternack, A. H., Collins‐Hooper, H., Ritvos, O., et al. (2020) · European Journal of Translational Myology · doi:10.4081/ejtm.2020.8904 · Cited by 4
Emerging therapeutic concepts for muscle and bone preservation/formation
Compston, J., & Fearon, K. C. H. (2015) · Bone · doi:10.1016/j.bone.2015.08.011 · Cited by 2
“Bimagrumab® is an anti-myostatin receptor antibody that increases skeletal muscle mass in mice beyond sole inhibition of myostatin and protects mice from glucocorticoid-induced muscle atrophy [23].”
BackgroundThe Future of Drugs in Sarcopenia
Zazzara, M. B., Penfold, R., & Onder, G. (2021) · Practical issues in geriatrics · doi:10.1007/978-3-030-80038-3_14 · Cited by 4
МЕТААНАЛИЗ АССОЦИАЦИИ ПОЛИМОРФИЗМА ГЕНА MSTN RS1805086 С СИЛОВЫМИ ПОКАЗАТЕЛЯМИ СПОРТСМЕНОВ
Aksenov, M. O. (2021) · Siberian Journal of Life Sciences and Agriculture · doi:10.12731/2658-6649-2021-13-2-303-335 · Cited by 2
“В настоящее время привлекает внимание исследование антител к ми - остатину, например MYO-029, BYM338, однако их эффективность мало - изучена [26, 27].”
Landi, F., Onder, G., & Rolland, Y. (2012) · Wiley eBooks · doi:10.1002/9781118338032.ch20 · Cited by 4
Sarkopenie und Frailty 2016: Auf getrennten Wegen
Bauer, J. M. (2016) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-016-1137-7 · Cited by 2
Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies
Abburi, K., Melson, E., Miras, A. D., & Papamargaritis, D. (2025) · Panminerva Medica · doi:10.23736/s0031-0808.25.05339-x · Cited by 1
Zhao, F., Yan, J., Liu, Z., Pan, D., Wang, Y., Li, L., Suo, S., Dang, K., Li, D., Dang, Y., et al. (2025) · Food Research International · doi:10.1016/j.foodres.2025.118157 · Cited by 1
van Krimpen, S. J., Simons, S. O., Schols, A. M. W. J., LANGEN, R. C. J., & Gosker, H. R. (2026) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2026.2620144 · Cited by 2
“Bimagrumab is an anti-ActRII antibody, and was shown in primary human skeletal myoblasts to counteract myostatin-or activin A-induced atrophy as well as impaired differentiation [105].”
Feraco, A., Camajani, E., Muscogiuri, G., Barrea, L., Colao, A., & Caprio, M. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00695-7 · Cited by 2
“Selective androgen receptor modulators (SARMs), myostatin inhibitors, and agents that modulate muscle metabolism show promise in early-phase studies, but their safety profiles, functional benefits, and long-term efficacy require further validation [ 52 – 55 ].”
Lisco, G., Tullio, A. D., Disoteo, O., Dicorato, P., Tortora, A., Geronimo, V. D., & Triggiani, V. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10033-w · Cited by 1
“By preventing ligand-induced activation of these receptors, bimagrumab promotes skeletal muscle hypertrophy by sparing myosin heavy chain from proteolytic degradation through inhibition of Smad2/3 phosphorylation [125], via a mechanism that is independent of the AKT/mTOR signaling pathway [126].”
Activin Signaling Inhibitors in Pulmonary Hypertension: A State‐of‐the‐Art Review
Rajagopal, S., Abueg, J., Hart, K. M., Lau, E., Martinez, E. C., Morrell, N. W., Preston, I. R., Sahay, S., Sood, N., Yu, P. B., et al. (2026) · Pulmonary Circulation · doi:10.1002/pul2.70353 · Cited by 2
Lang, G., Dernoncourt, V., & Bisson, J. (2015) · Muscle and Nerve · doi:10.1002/mus.24273 · Cited by 2
Han, W., Bai, X.-J., Han, L., Chen, X., & Sun, X. (2021) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-021-06183-8 · Cited by 1
Barry, D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-43044-9.00217-x · Cited by 2
Bloomgarden, Z. T. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13379 · Cited by 1
Drug Delivery Systems for Muscles
Naito, M., & Hori, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-55653-1_6 · Cited by 3
Ohsawa, Y., Nishimatsu, S., Fujino, M., & Sunada, Y. (2016) · Springer eBooks · doi:10.1007/978-4-431-55678-7_5 · Cited by 1
Béchir, N., Pecchi, É., Vilmen, C., Bernard, M., Bendahan, D., & Giannesini, B. (2018) · Muscle & Nerve · doi:10.1002/mus.26306 · Cited by 1
Vaughan, D., Mitchell, R., Kretz, O., Chambers, D. J., Lalowski, M. M., Amthor, H., Ritvos, O., Pasternack, A. H., Matsakas, A., Vaiyapuri, S., et al. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.047555 · Cited by 1
“These include the use of activin/myostatinbinding proteins, such as follistatin, and receptor-blocking antibodies (Amthor et al., 2004; Lach-Trifilieff et al., 2014).”
BackgroundBackground and Management of Muscular Atrophy
Cseri, J. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.90959 · Cited by 2
Osteoporosis associated with chronic kidney disease
Ott, S. M., & Elder, G. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00054-x · Cited by 1
Phenotypic classification and biochemical profile of obesity for cardiovascular prevention
Perrone, M. A., Dasari, J. B., Intorcia, A., Gualtieri, P., Marche, M., Luozzo, M. D., Merra, G., Bernardini, S., Romeo, F., & Sergi, D. (2020) · Gazzetta Medica Italiana Archivio per le Scienze Mediche · doi:10.23736/s0393-3660.20.04259-x · Cited by 1
Vaughan, D., Kretz, O., Alqallaf, A., Mitchell, R., der Heide, J. L. V., Vaiyapuri, S., Matsakas, A., Pasternack, A. H., Collins‐Hooper, H., Ritvos, O., et al. (2020) · European Journal of Translational Myology · doi:10.4081/ejtm.0.8904 · Cited by 1
Novel Insights into the Use of Biologicals in Idiopathic Inflammatory Myopathies
Parchani, A., Sudan, A., Singh, S., Singh, A., & Pathania, M. (2022) · Physiology · doi:10.5772/intechopen.106277 · Cited by 1
Durán, J., & Estrada, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00381 · Cited by 1
“Interestingly, in myostatin-null mice, treatment with anti-ActRIIB antibody causes additive muscle hypertrophy, suggesting that ActRII receptor ligands regulate muscle growth (Lee et al., 2005; Lach-Trifilieff et al., 2014).”
BackgroundShi, A., Hillege, M. M., Noort, W., Offringa, C., Wu, G., Forouzanfar, T., Hoogaars, W. M. H., Wüst, R. C. I., & Jaspers, R. T. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.30.555466 · Cited by 1
Shi, A., Hillege, M. M. G., Noort, W., Offringa, C., Wu, G., Tim, F., Hoogaars, W. M. H., Wüst, R. C. I., & Jaspers, R. T. (2026) · Communications Biology · doi:10.21203/rs.3.rs-5136404/v1 · Cited by 1
Two Activin Type 2B Receptors from Sea Bream Function Similarly in vitro
Nadjar-Boger, E., Krol, E., & Funkenstein, B. (2016) · Biological Bulletin · doi:10.1086/bblv230n1p56
“56 functions as a negative regulator of skeletal muscle growth in mammals (Lee, 2004; Kollias and McDermott, 2008).”
BackgroundC URRENT OPINION Inclusion body myositis: update
Lahouti, A. H., Amato, A. A., & Christopher‐Stine, L. (2014)
Global MEF2 Target Gene Analysis in Skeletal and Cardiac Muscle
Wales, S. (2016) · YorkSpace (York University)
Recent Development of Therapy for Muscular Dystrophy
Toda, T. (2014) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.103.2820
Vishnu, P. G., Bhattacharya, T. K., Bhushan, B., Kumar, T. V., CHATTERJEE, R. N., Paswan, C., Prasad, A. R., Divya, D., & Dushyanth, K. (2019) · Research in Veterinary Science · doi:10.1016/j.rvsc.2019.08.025
Zhang, Y., Zhu, J., Kim, S., Romero, M. M., Even, K. A., Kurita, T., & Woodruff, T. K. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.16.154385
“Antibodies and small molecules that target activin have also been developed(19, 20).”
BackgroundTorres, J. I. T., Reyes, M. M., Collazos, J. E. M., Ríos, I. D. P., & Rodríguez-Corredor, L. C. (2021) · Archivos de Medicina (Manizales) · doi:10.30554/archmed.21.2.3897.2021 · Cited by 2
“Un estado infeccioso instaurado promueve el catabolismo muscular y reduce el anabolismo mediante la señalización de citoquinas proinflamatorias en la fase aguda, ya conocidas como TNF-α, IL-1β e IL-6, aunque se han identificado otros mediadores en el catabolismo muscular como los miembros de la superfamilia β del fact…”
BackgroundCulver, A. E., Hamang, M., Wang, Y., White, E., Gawrieh, S., Vuppalanchi, R., Chalasani, N., Dai, G., & Yaden, B. C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.27.441640
“Results from these clinical studies may provide information pertinent to the utility of such therapeutics in liver disease [67].”
BackgroundAksenov, M. O., & Kruszewski, M. (2022) · Research Square · doi:10.21203/rs.3.rs-1342135/v1
Landi, F., Onder, G., & Rolland, Y. (2021) · Wiley eBooks · doi:10.1002/9781119597896.ch25
Advances in Skeletal Muscle Health and Disease
Iannotti, F. A. (2022) · Physiology · doi:10.5772/intechopen.100953
Sarcopenia: Current Topics and Future Perspective
Yamada, M., Kinoshita, K., Satake, S., Matsui, Y., & Arai, H. (2022) · Springer eBooks · doi:10.1007/978-981-16-7977-3_12 · Cited by 1
Sinha, A., Park, J. M., Gulzar, N., Pandya, D. N., Wadas, T. J., & Scott, J. K. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.31.578303
Rodrigues, M. R. D. C. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2023.tde-05022024-134049 · Cited by 2
David J. Glass elected to the U.S. National Academy of Sciences
Lee, S., Spiegelman, B. M., & Campbell, K. P. (2024) · Skeletal Muscle · doi:10.1186/s13395-024-00343-5
KLF10: a point of convergence in cancer cachexia
Epstein, S. A., Doles, J. D., & Dasgupta, A. (2024) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000711 · Cited by 1
“ActRII receptors have also been the target of a clinical trial as they were shown to be successful in preclinical trials by retaining muscle force and mass [34].”
Sarkopene Adipositas im Alter: Ursachen, Folgen und Behandlungsansätze
Rippl, M., Drey, M., & Schluessel, S. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2492-9415
“…in der kürzlich publizierten TRAVERSE-Studie wider-legt werden, welche kein erhöhtes Risiko für höhergradige kardio-vaskuläre Ereignisse bei Patienten mit Testosteronsubstitution im Vergleich zu Placebo zeigte, sodass dieser Therapieansatz zukünf-tig weiterhin vielversprechend erscheint [57].”
High-fat diet induced obesity and anti-activin receptor antibody: Effects on bone properties in mice
Bromer, F. D., Lodberg, A., Sylow, L., Carlsson, M., Andersen, C. B. F., Thomsen, J. S., & Brüel, A. (2025) · Bone Reports · doi:10.1016/j.bonr.2025.101878
Gerlach, I., Koch, M., Gatto, G., Lackmann, J., Lehmann, H. C., Schroeter, M., & Kohle, F. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02277-z
“Thereby, the ligand-receptor interaction of Myostatin and Activin A was shown to be disrupted [43, 64].”
InfluentialThe function of Activin receptor type IIB signaling in adult skeletal muscle
Relizani, K. (2014) · theses.fr (ABES) · doi:10.70675/20978d43z02f0z4a1ezb428zf5dab86d9abf
Parenté, A. (2019) · theses.fr (ABES) · doi:10.70675/3d9a23f5z3546z46f1z957cz5d167994539d
Oxytocin, as a hormonal treatment for cachexia in preclinical models
Benoni, A. (2022) · theses.fr (ABES) · doi:10.70675/f14dd835z1cb6z471ez8accz6ccfa7f21ff1
Jacquez, Q., Peabody, J., Acosta, E. H., Chackerian, B., & Endicott, S. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.06.716693
Skeletal muscle biomass as an underappreciated fate of glucose
Wackerhage, H., Eggelbusch, M., Hulmi, J. J., & Mäntyselkä, S. (2026) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00295.2026
Zhang, N., Long, Y., Xu, Z., Chen, G., Wang, A., Chen, W., Chen, Z., Liang, Z., Leung, K., & Chen, L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.09.737400
“Genetic deletion or pharmacological inhibition of ActRII receptors has consistently demonstrated significant muscle hypertrophy and improved metabolic profiles in preclinical models [16-18] .”
Metadata
- Authors
- Lach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., Hatakeyama, S., & Glass, D. J.
- Affiliations
- MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, Basel, Switzerland
- Novartis (Switzerland) (CH)
- Development and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA
- Novartis Institutes for BioMedical Research (CH)
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2014-02-01
- Volume
- 34
- Issue
- 4
- Pages
- 606-618
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC3911487
- OpenAlex
- W2102107385
- Semantic Scholar
- 9ec58206f235e018d6953a27e975ae19a1c51271
- Cited by
- 306
- References
- 58
- Citations by year
- 2026: 22 · 2025: 16 · 2024: 19 · 2023: 21 · 2022: 20 · 2021: 37 · 2020: 29 · 2019: 28 · 2018: 25 · 2017: 18 · 2016: 29 · 2015: 21 · 2014: 19
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Molecular and Cellular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis
- MorphoSys
- Novartis Pharma
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- activin type II receptor, bimagrumab, myostatin, skeletal muscle hypertrophy, muscle atrophy, Smad2/3 phosphorylation, skeletal myoblast differentiation, activin A, GDF11, muscle weakness, myosin heavy chain degradation, muscle mass regulation
- MeSH terms
- Animals, Antibodies, Monoclonal, Atrophy, Cell Differentiation, Humans, Hypertrophy, Signal Transduction, Muscle, Skeletal, Antibodies, Blocking, Activins, Activin Receptors, Type II, Myoblasts, Skeletal, Mice, Smad2 Protein, Smad3 Protein, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.